keyword
MENU ▼
Read by QxMD icon Read
search

Gastrointestinal neuroendocrine tumor

keyword
https://www.readbyqxmd.com/read/29143892/update-in-the-therapy-of-advanced-neuroendocrine-tumors
#1
REVIEW
Inbal Uri, Shani Avniel-Polak, David J Gross, Simona Grozinsky-Glasberg
Neuroendocrine tumors (NETs) are rare neoplasms, with an estimated annual incidence of ~ 6.9/100,000. NETs arise throughout the body from cells of the diffuse endocrine system. More than half originate from endocrine cells of the gastrointestinal tract and the pancreas, thus being referred to as gastroenteropancreatic NETs (GEP-NETs). The only treatment that offers a cure is surgery; however, most patients are diagnosed with metastatic disease, and curative surgery is usually not an option. These patients can be offered long-term systemic treatment, for both symptomatic relief and tumor growth suppression...
November 16, 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/29142475/predictive-factors-associated-with-carcinoid-syndrome-in-patients-with-gastrointestinal-neuroendocrine-tumors
#2
Beilei Cai, Michael S Broder, Eunice Chang, Tingjian Yan, David C Metz
AIM: To discover unknown factors associated with carcinoid syndrome (CS) with the goal of earlier diagnosis of CS. METHODS: In this retrospective case-control study using United States administrative claims, patients (≥ 18 years) newly-diagnosed with gastrointestinal neuroendocrine tumors (GI NETs) without CS (controls) were exactly matched to patients with CS (cases) based on NET diagnosis date at a 3-to-1 ratio. Study index date was first CS diagnosis (controls: same distance from NET diagnosis as cases)...
October 28, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29137468/epidemiology-of-neuroendocrine-tumors-in-an-iranian-population
#3
Mona MalekZadeh, Sam Alahyari, Saleh Sandoughdaran, Hanieh Zham
Neuroendocrine tumors (NETs) are a rare and heterogeneous group of malignancies most commonly found in the gastrointestinal system. In this study, we examined the epidemiology of NETs in an Iranian population. The incident NET cases diagnosed between January 1, 2009 and December 31, 2014 were collected from databases of three hospitals in Tehran (Shoada-e-Tajrish Hospital, Imam Hossein Hospital and Pars Hospital).  A total of 291 cases with NET diagnosis were identified. The most common NET location was gastrointestinal (71...
October 2017: Archives of Iranian Medicine
https://www.readbyqxmd.com/read/29136686/-clinicopathologic-and-molecular-characteristics-of-malignant-gastrointestinal-neuroectodermal-tumors
#4
M Zhao, T W Zhao, J Ma, C Y Wu, L Chen, G Q Ru, X L He
Objective: To investigate the clinicopathologic and molecular characteristics, diagnostic, differential diagnostic and prognostic features of malignant gastrointestinal neuroectodermal tumor. Methods: Two cases of malignant gastrointestinal neuroectodermal tumor were retrieved; the clinical and radiologic features, histomorphology, immunophenotype, molecular genetics and prognosis were analyzed and the relevant literature reviewed. Results: Case 1 was a 57-year-old male, presented with recurrent abdominal pain and melena...
November 8, 2017: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
https://www.readbyqxmd.com/read/29116005/composite-intestinal-adenoma-microcarcinoid-in-the-colon-and-rectum-a-case-series-and-historical-review
#5
Mi-Jung Kim, Eun-Jung Lee, Do Sun Kim, Doo Han Lee, Eui Gon Youk, Hyun-Jung Kim
BACKGROUND: Composite intestinal adenoma-microcarcinoid (CIAM) is a rare colorectal lesion that mostly comprises a conventional adenomatous component with a minute proportion of neuroendocrine (NE) component. Although microcarcinoids are well-recognized in the setting of chronic inflammatory disorders of the gastrointestinal tract, large intestinal microcarcinoids associated with intestinal adenoma are exceedingly rare and their clinicopathologic characteristics are yet to be elucidated...
November 7, 2017: Diagnostic Pathology
https://www.readbyqxmd.com/read/29081664/impact-of-prior-therapies-on-everolimus-activity-an-exploratory-analysis-of-radiant-4
#6
Roberto Buzzoni, Carlo Carnaghi, Jonathan Strosberg, Nicola Fazio, Simron Singh, Fabian Herbst, Antonia Ridolfi, Marianne E Pavel, Edward M Wolin, Juan W Valle, Do-Youn Oh, James C Yao, Rodney Pommier
BACKGROUND: Recently, everolimus was shown to improve median progression-free survival (PFS) by 7.1 months in patients with advanced, progressive, well-differentiated, nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) tract compared with placebo (HR, 0.48; 95% CI, 0.35-0.67; P<0.00001) in the Phase III, RADIANT-4 study. This post hoc analysis evaluates the impact of prior therapies (somatostatin analogs [SSA], chemotherapy, and radiotherapy) on everolimus activity...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29066973/from-resistance-to-sensitivity-insights-and-implications-of-biphasic-modulation-of-autophagy-by-sunitinib
#7
REVIEW
Amal Kamal Abdel-Aziz, Ashraf B Abdel-Naim, Samia Shouman, Saverio Minucci, Mohamed Elgendy
Sunitinib, a multityrosine kinase inhibitor, is currently the standard first-line therapy in metastatic renal cell carcinoma (mRCC) and is also used in treating patients with pancreatic neuroendocrine and imatinib-resistant gastrointestinal stromal tumors (GIST). Nevertheless, most patients eventually relapse secondary to intrinsic or acquired sunitinib resistance. Autophagy has been reported to contribute to both chemo-sensitivity and -resistance. However, over the last few years, controversial regulatory effects of sunitinib on autophagy have been reported...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29061283/liver-resection-for-metastases-not-of-colorectal-neuroendocrine-sarcomatous-or-ovarian-ncnso-origin-a-multicentric-study
#8
Ismail Labgaa, Ksenija Slankamenac, Erik Schadde, Ghalib Jibara, Kutaiba Alshebeeb, Gilles Mentha, Pierre-Alain Clavien, Myron Schwartz
BACKGROUND: Liver resection is a well-established treatment for colorectal, neuroendocrine and sarcomatous metastases but remains ill-defined for metastases from other primary sites. This study aimed to analyze the outcomes of hepatic resection for metastases not of colorectal, neuroendocrine, sarcomatous, or ovarian (NCNSO) origin and to identify predictors of outcome. METHODS: Retrospective analysis of patients undergoing resection for NCNSO metastases in three western centers...
October 7, 2017: American Journal of Surgery
https://www.readbyqxmd.com/read/29055056/everolimus-in-advanced-progressive-well-differentiated-non-functional-neuroendocrine-tumors-radiant-4-lung-subgroup-analysis
#9
Nicola Fazio, Roberto Buzzoni, Gianfranco Delle Fave, Margot E Tesselaar, Edward Wolin, Eric Van Cutsem, Paolo Tomassetti, Jonathan Strosberg, Maurizio Voi, Lida Bubuteishvili-Pacaud, Antonia Ridolfi, Fabian Herbst, Jiri Tomasek, Simron Singh, Marianne Pavel, Matthew H Kulke, Juan W Valle, James C Yao
In the phase III RADIANT-4 study, everolimus improved median progression-free survival (PFS) by 7.1 months in patients with advanced, progressive, well-differentiated (grade 1 or grade 2), non-functional lung or gastrointestinal neuroendocrine tumors (NETs) vs placebo (hazard ratio, 0.48; 95% confidence interval [CI], 0.35-0.67; P < .00001). This exploratory analysis reports the outcomes of the subgroup of patients with lung NETs. In RADIANT-4, patients were randomized (2:1) to everolimus 10 mg/d or placebo, both with best supportive care...
October 21, 2017: Cancer Science
https://www.readbyqxmd.com/read/29040195/grade-assignment-by-ki-67-proliferative-index-mitotic-count-and-phosphohistone-h3-count-in-surgically-resected-gastrointestinal-and-pancreatic-neuroendocrine-tumors
#10
Claire E Murphy, Kinsey A McCormick, Veena Shankaran, Deepti M Reddi, Paul E Swanson, Melissa P Upton, Antonios Papanicolau-Sengos, Sara Khor, Maria Westerhoff
OBJECTIVES: The aim of this study was to evaluate the concordance in grade assignment for gastroenteropancreatic neuroendocrine tumors using mitotic count (MC), Ki-67 proliferative index (KPI), and phosphohistone H3 count (PHH3C). METHODS: Resected gastroenteropancreatic neuroendocrine tumors were graded based on MC, KPI, and PHH3C. Concordance was determined using a weighted κ statistic. Median survival across each grade category was determined using Kaplan-Meier methods...
November 2017: Pancreas
https://www.readbyqxmd.com/read/29032398/analysis-of-mir-96-and-mir-133a-expression-in-gastrointestinal-neuroendocrine-neoplasms
#11
Rakesh Mandal, Heather Hardin, Rebecca Baus, William Rehrauer, Ricardo V Lloyd
Grading of gastrointestinal neuroendocrine neoplasms (GI-NENs) relies mainly on mitotic activity and Ki-67 proliferation index. It is often difficult to predict metastatic potential of these neoplasms. Recent studies have shown that GI-NENs express a wide spectrum of microRNAs. We examined two microRNAs (miR-96 and miR-133a) that were recently identified in GI-NENs to determine if they could assist in evaluating the biological behavior of these neoplasms. A tissue microarray (TMA) was constructed with 51 primary GI-NENs, mainly from the small intestine and metastatic tumors from the same cases, including liver metastases (N = 20) and lymph node metastases (N = 33)...
October 14, 2017: Endocrine Pathology
https://www.readbyqxmd.com/read/29026467/chromogranin-a-as-a-biochemical-marker-for-neuroendocrine-tumors-a-single-center-experience-at-royal-hospital-oman
#12
Elham S Al-Risi, Fatma S Al-Essry, Waad-Allah S Mula-Abed
OBJECTIVES: To evaluate the significance of serum chromogranin A (CgA) status in patients with and without different neuroendocrine tumors (NETs) by conducting a retrospective assessment of the diagnostic utility and limitations of CgA as a biomarker for NETs in a tertiary care hospital in Oman. METHODS: We conducted a retrospective analysis of CgA requests referred to the Clinical Biochemistry Laboratory, Royal Hospital, Oman over a 24-month period (April 2012 to March 2014)...
September 2017: Oman Medical Journal
https://www.readbyqxmd.com/read/29020456/the-management-of-neuroendocrine-tumors-a-nutritional-viewpoint
#13
Marco Gallo, Giovanna Muscogiuri, Genoveffa Pizza, Rosaria Maddalena Ruggeri, Luigi Barrea, Antongiulio Faggiano, Annamaria Colao
Nutritional status in patients with neuroendocrine tumours (NETs), especially of gastroenteropancreatic origin, can be deeply affected by excessive production of gastrointestinal hormones, peptides, and amines, which can lead to malabsorption, diarrhoea, steatorrhea, and altered gastrointestinal motility. Besides, the surgical and/or medical management of NETs can lead to alteration of gastrointestinal secretory, motor, and absorptive functions, with both dietary and nutritional consequences. Indeed, disease-related malnutrition is a frequently encountered yet both underrecognized and understudied clinical phenomenon in patients with NETs, with substantial prognostic and socioeconomic consequences...
October 11, 2017: Critical Reviews in Food Science and Nutrition
https://www.readbyqxmd.com/read/29018988/circulating-chromogranin-a-and-its-fragments-as-diagnostic-and-prognostic-disease-markers
#14
REVIEW
Angelo Corti, Fabrizio Marcucci, Tiziana Bachetti
Chromogranin A (CgA), a secretory protein released in the blood by neuroendocrine cells and neurons, is the precursor of various bioactive fragments involved in the regulation of the cardiovascular system, metabolism, innate immunity, angiogenesis, and tissue repair. After the original demonstration that circulating CgA can serve as a biomarker for a wide range of neuroendocrine tumors, several studies have shown that increased levels of CgA can be present also in the blood of patients with cardiovascular, gastrointestinal, and inflammatory diseases with, in certain cases, important diagnostic and prognostic implications...
October 10, 2017: Pflügers Archiv: European Journal of Physiology
https://www.readbyqxmd.com/read/29016403/the-influence-of-tumor-stage-on-the-prognostic-value-of-ki-67-index-and-mitotic-count-in-small-intestinal-neuroendocrine-tumors
#15
Yu Sun, Christine Lohse, Thomas Smyrk, Timothy Hobday, Trynda Kroneman, Lizhi Zhang
Tumor cell proliferation rate determined by either Ki-67 index or mitotic count (MC) has shown to be a prognostic factor for gastrointestinal neuroendocrine tumors in general, and after its incorporation in the 2010 World Health Organization tumor grading system, it has become essentially mandatory in pathology reports for all gastrointestinal neuroendocrine tumors, regardless of tumor location. Nevertheless, clinical significance for the Ki-67 index or MC has not been well demonstrated in small intestinal neuroendocrine tumor (SINET), especially those without distant metastasis, the majority of which have very low proliferation rates...
October 9, 2017: American Journal of Surgical Pathology
https://www.readbyqxmd.com/read/28990511/sunitinib-in-the-treatment-of-thyroid-cancer
#16
Ferrari Silvia Martinaa, Centanni Marco, Virili Camilla, Miccoli Mario, Ferrari Paola, Ruffilli Ilaria, Ragusa Francesca, Antonelli Alessandro, Fallahi Poupak
BACKGROUND: Sunitinib (SU11248) is an oral, small-molecule, multi-targeted tyrosine kinase inhibitor (TKI), that inhibits receptors for platelet-derived growth factor (PDGF-Rs) and vascular endothelial growth factor receptors (VEGFRs), c-KIT, fms-related tyrosine kinase 3 (FLT3) and RET. The concurrent inhibition of these pathways reduces tumor vascularization and causes cancer cell apoptosis, inducing a tumor shrinkage. Sunitinib is approved for the treatment of imatinib-resistant gastrointestinal stromal tumor (GIST), renal carcinoma, and pancreatic neuroendocrine tumors...
October 6, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/28982917/gastric-spindle-cell-neuroendocrine-tumor-mimicking-gastrointestinal-stromal-tumor-unique-morphology-and-diagnostic-pitfall
#17
Alexandria A Lee, Nishant Poddar, Muhammad B Hammami, Jula Veerapong, Dengfeng Cao, Jin-Ping Lai
Gastric neuroendocrine tumors (GNETs) with spindle cell morphology are extremely rare. We present a case of a 49-year-old female patient with a history of systemic lupus erythematosus, Sjogren's syndrome, and gastroesophageal reflux disease. She was initially thought to have a spindle cell gastrointestinal stromal tumor per histological studies of the fundic polypectomy samples. Immunohistochemically, the tumor cells were negative for CD117, and CD34, but positive for chromogranin, synaptophysin, and CD56 with a 6% Ki-67 index, consistent with a spindle cell-type well differentiated neuroendocrine tumor, World Health Organization (WHO) Grade 2...
October 2017: Anticancer Research
https://www.readbyqxmd.com/read/28982884/compensation-claims-for-sub-substandard-care-of-patients-with-gastroentero-pancreatic-neuroendocrine-tumors-a-nationwide-descriptive-study-of-cases-between-2005-2016-in-norway
#18
Kari F Desserud, Ida Bukholm, Jon Arne Søreide
BACKGROUND: Management of patients with neuroendocrine tumors of the gastrointestinal tract or pancreas (GEP-NENs) poses diagnostic and therapeutic challenges. This study described the medico-legal claims reported to a national governmental system that oversees compensation to patients with GEP-NENs Materials and Methods: An electronic search of the Norwegian System of Compensation to Patients database was performed to identify claims evaluated between 2005-2016. The clinical information and the medico-legal evaluation were reviewed...
October 2017: Anticancer Research
https://www.readbyqxmd.com/read/28970728/real-world-treatment-patterns-of-gastrointestinal-neuroendocrine-tumors-a-claims-database-analysis
#19
Al B Benson Iii, Michael S Broder, Beilei Cai, Eunice Chang, Maureen P Neary, Elya Papoyan
AIM: To describe real-world treatment patterns of gastrointestinal neuroendocrine tumors (GI NET). METHODS: In this retrospective cohort study, we used 2009-2014 data from 2 United States commercial claims databases to examine newly pharmacologically treated patients using tabular and graphical techniques. Treatments included somatostatin analogues (SSA), cytotoxic chemotherapy (CC), targeted therapy (TT), interferon (IF) and combinations. We identified patients at least 18 years of age, with ≥ 1 inpatient or ≥ 2 outpatient claims for GI NET who initiated pharmacologic treatment from 7/1/09-6/30/14...
September 7, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28937380/bilateral-ovarian-metastases-as-the-presenting-manifestation-of-lung-carcinoid-in-a-50-year-old-woman-case-study-and-review-of-literature
#20
Subhashis Mitra, Amiya Jhunjhunwala, Hema Chakraborty
Neuroendocrine tumors (NETs) are neoplasms arising from dispersed neuroendocrine cells, localized to the gastrointestinal tract (GIT), lungs, adrenal medulla, and other sites. The term "carcinoid tumor" is usually limited to NETs of the lung and GIT. Ovarian carcinoids are uncommon, accounting for 0.1% of ovarian malignancies and 5% of all NETs. Primary ovarian tumors arise in pure form or as a component of teratomas, while ovarian NET metastases are predominantly from gastrointestinal primaries. To the best of our knowledge, there are only two previous reports of bronchopulmonary carcinoids (PCs) metastasizing to the ovaries...
July 2017: Indian Journal of Pathology & Microbiology
keyword
keyword
40224
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"